Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165398 | 0.83 | POLB (0.63) | POLBHTTMAPK1KMT2ACYP2C19 | |
| SCHEMBL14005999 | 0.81 | POLB (0.66) | POLBHTTMAPK1KMT2ACYP2C19 | |
| SCHEMBL3374529 | 0.80 | POLB (0.53) | POLBHTTMAPK1KMT2AAGTR1 | |
| SCHEMBL2733465 | 0.80 | POLB (0.60) | POLBHTTMAPK1KMT2ACYP2C19 | |
| SCHEMBL11096851 | 0.76 | POLB (0.52) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL583 | 0.70 | AGTR1 (0.53) | AGTR1 | |
| SCHEMBL3079356 | 0.70 | CYP11B1 (0.71) | POLBHTT | |
| SCHEMBL10639259 | 0.70 | POLB (0.49) | POLBHTTMAPK1KMT2AALDH1A1 | |
| SCHEMBL5012601 | 0.69 | SMN1; SMN2 (0.41) | POLBHTTMAPK1KMT2ACYP2C19 | |
| SCHEMBL9597447 | 0.69 | CYP2C19 (0.59) | POLBHTTMAPK1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | POLB 2063/4885HTT 4778/4885MAPK1 1627/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | POLB 2063/4885HTT 4778/4885MAPK1 1627/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | POLB 2063/4885HTT 4778/4885MAPK1 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.